Merck KGaA 4th-quarter 2014 earnings beat expectations

3 March 2015

Germany’s Merck KGaA (MRK: DE) this morning reported financial results showing that group sales for the full year 2014 increased 3.7% to 11.5 billion euros ($12.90 billion), exceeding the 11 billion euros to 11.2 billion euros forecast in November.

Net income came in at 1.2 billion euros, a dip of 0.2%. Earnings per share pre onetime items advanced, taking into account the 1:2 split in June 2014, by 4.8% to 4.60 euros versus 4.39 euros in 2014.

Fourth-quarter earnings before interest, taxes, depreciation and amortization (EBITDA) and one-offs rose 10.5% to 878 million euros, beating the 870 million euros expected on average by analysts polled by Reuters. Merck’s shares edged up 1.9% to 96.08 euros in morning trading.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK